Analyse des 3D-Faserspritzverfahrens zur Fertigung komplexer und funktionsintegrierter RTM-Strukturbauteile

Figure S3. Trends in peripheral lymphocyte numbers and percentages over time on treatment. Significant decreases in mean peripheral lymphocyte numbers (left panel, p = 0.007) and percentages (right panel, p = 0.018) occurred over time on treatment and follow-up. Linear mixed effect model was used for comparisons. Mean values, represented by solid circles, are connected by a trendline in each graph. Rectangles at each time point extend to the 1st and 3rd quartiles. Vertical lines at each time point extend to 1.5 x the interquartile range. Dashed lines indicate upper and lower limits of normal values. Each treatment cycle length is 28 days. Samples were obtained on Day 1 of each cycle for patients in Cohorts A and B, and on Day 0 of each cycle for patients in Cohort C. An analysis including all patients is shown. Similar trends were seen for each cohort when analyzed individually (data not shown). C, treatment cycle

Additional file 1: of Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting

Figure S1. Schedule of Melanoma GVAX treatment, biospecimen collection and clinical assessment. Asterisks denote vaccine administration (Day 1 of each cycle). Cyclophosphamide was administered one day prior to each vaccine administration for patients in cohort C. Peripheral blood (PB) was collected at baseline (C1D1, or C1D0 for Cohort C) and prior to each vaccination [C2D1(D0), C3D1(D0) and C4D1(D0)], Treatment cycle length is 28 days. C, treatment cycle; D, treatment day